REG - Sareum Holdings PLC - Notice of Results and Investor Presentation

Sareum HoldingsAnnouncement

03/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260303:nRSC0060Va&default-theme=true

RNS Number : 0060V  Sareum Holdings PLC  03 March 2026

 

Sareum Holdings PLC

 

("Sareum" or the "Company")

 

Notice of Interim Results for the Year Ended 31 December 2025 and Investor
Presentation

 

Cambridge, UK, 3 March 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage
biotechnology company developing next-generation kinase inhibitors for
autoimmune disease and cancer, will announce its unaudited financial results
for the six months ended 31 December 2025 on Thursday, 12 March 2026.

The Company will also be holding a live presentation to investors on Thursday,
12 March 2026 at 14:00 GMT via the Investor Meet Company platform.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
11 March 2026, 09:00 GMT, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet SAREUM
HOLDINGS PLC via:
https://www.investormeetcompany.com/sareum-holdings-plc/register-investor
(https://www.investormeetcompany.com/sareum-holdings-plc/register-investor)

Investors who already follow SAREUM HOLDINGS PLC on the Investor Meet Company
platform will automatically be invited.

A copy of the presentation will be made available on the Company's website
following the presentation.

- Ends -

 

For further information:

 

 Sareum Holdings plc

 Stephen Parker, Executive Chairman                  01223 497700

                                                     ir@sareum.co.uk
 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Singer Capital Markets (Joint Corporate Broker)     020 7496 3000

 Phil Davies

 Oberon Capital (Joint Corporate Broker)             020 3179 5300

 Mike Seabrook / Nick Lovering

 ICR Healthcare (Financial PR)                       020 3709 5700

 Jessica Hodgson / Davide Salvi

 

 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, with a planned
initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for certain haematological cancers and has recently initiated a
preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory
diseases such as multiple sclerosis and Parkinson's disease

The Company has recently acquired the license for SRA737, a clinical-stage
Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA
damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(http://www.sareum.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORAKBBDOBKDONK



            Copyright 2019 Regulatory News Service, all rights reserved